Derived from a lymph node metastasis of a female with Acral lentiginous melanoma (ALM). Sensitive to TKI (Dasatinib, Sunitinib)
| Inventor | Institute |
|---|---|
| Ghanem Elias, Ahmad Najem | Universit? libre de Bruxelles |
| SKU: | 161606 |
|---|---|
| Product description: | Drug response: Sensitive to TKI (Dasatinib, Sunitinib). |
| Gender: | Female |
| CRISPR: | No |
| Parental cell line: | Ham’s F10 melanoma culture medium (HMCM) |
| Model description: | This cell line displays a Proliferative/ Melanocyte-like phenotype |
| Disease: | Cancer |
| Cat. #: | 161606 |
|---|---|
| Cancer types: | Skin cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Lymphatic |
| Gender: | Female |
| Model: | C-KIT: Amp; NRAS: Q61K |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Melanoma |
| Primary citation: | Gembarska et al. 2012. Nat Med 18, 12391247. PMID: 22820643 |
| Initial handling information: | The frozen culture should be stored in liquid nitrogen upon arrival or thaw the vial and initiate the culture as soon as possible upon receipt |
|---|---|
| Format: | Frozen |
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry Ice |
| Growth medium: | Hamâs F10 supplemented with 10% of fetal calf serum (FCS), with L-glutamine (1mM), penicillin (100 IU/ml), and streptomycin (100 Â?g/ml). Renewal 2 to 3 times per week |
| Subculture routine: | Split sub-confluent cultures (70-80%) 1:3 to 1:6 |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| Biosafety level: | 2 |
| References: |
Sabbah et al. 2021. Mol Cancer Res. 19(7):1221-1233. PMID: 33741716 Krayem et al. 2014. Eur J Cancer. 50(7):1310-20. PMID: 24559688 Krayem et al. 2018. Oncotarget. 9(61):31888-31903. PMID: 30159130 Soumoy et al. 2020. Cancers (Basel). 12(5):1323. PMID: 32455924 Porcelli et al. 2015. J Transl Med. 13:26. PMID: 25623468 Wouterset al. 2020. Nat Cell Biol. 22(8):986-998. PMID: 32753671 Verfaillie et al. 2015. Nat Commun 6, 6683. PMID: 25865119 Aftimos et al. 2013. Int J Oncol. 43(3)… |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.